Bristol-Myers Squibb to Buy Celgene, Combining Two Cancer-Drug Leaders

Bristol-Myers Squibb agreed to acquire Celgene for about $74 billion, creating a cancer-drug powerhouse, but one with questions about its long-term prospects.

from WSJ.com: US Business https://on.wsj.com/2F7ZDAy
via IFTTT